ScPharmaceuticals up on launch update of heart failure therapy
30/01/2023 15:47
** Shares of drug developer scPharmaceuticals Inc SCPH.O
rise 3.5% to $5.89
** Co says it plans to commercially launch its heart failure
therapy, Furoscix, on Feb. 20
** The therapy, to treat congestion of heart due to fluid
overload among patients with heart failure, was approved by U.S.
FDA in October last year
** SCPH shares have gained ~20% in past six months
(Reporting by Raghav Mahobe)
((Raghav.Mahobe@thomsonreuters.com))